With its world-class clinics and ALS specialists, Canada is well positioned to be a leader in clinical trial access.
June 1, 2022
History and context Canada has a rich history in ALS clinical trials. Though an ALS research community developed here alongside the rest of the world in the late 1970s and 1980s, Dr. Andrew Eisen at Vancouver General Hospital is widely... Read More
May 31, 2022
TDP-43 is a protein that lives in the nucleus of our cells. But in at least 97 per cent of ALS patients, TDP-43 somehow finds its way out of the nucleus – also called “mislocalization” – and starts to “clump”... Read More
May 26, 2022
Researchers are at a critical juncture in the study of ALS, with more pieces of the ALS biology puzzle available today than ever before. As labs continue to put the pieces together and identify new targets for therapeutics, work is... Read More
May 18, 2022
One of the first things that happens in neurodegenerative diseases is that neurons stop communicating with each other. And when neurons stop talking, they die. One hypothesis for this phenomenon is that the neurons get overly excited — so excited... Read More
May 11, 2022
Now more than ever it is important to know the issues that matter to you before you cast your ballot on Thursday, June 2nd , 2022. ALS Canada reached out to each major political party to get more details about... Read More
May 6, 2022
Over the past several years, ALS Canada, together with the ALS community and a coalition of patient groups across Canada, has raised the alarm about the consequences of the proposed changes to Patented Medicine Prices Review Board (PMPRB) regulations for... Read More
